Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Arimidex gains U.S. FDA approval for breast cancer in postmenopausal women
October 23rd, 2005
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has granted full approval status to Arimidex (anastrozole) for the adjuvant treatment of hormone receptor-positive early breast cancer (EBC) in postmenopausal women. Arimidex is the only aromatase inhibitor with study results representing a full 5 years of efficacy and safety data in this primary adjuvant setting, and is now the only aromatase inhibitor that has proven superior disease-free survival over tamoxifen in the primary adjuvant setting. This long-term data for Arimidex provides clinicians and patients an opportunity to make the most informed decision about their primary...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
